Retatrutide vs Tirzepatide vs Semaglutide: Triple Agonist vs Dual Agonist vs Single — The Complete Research Comparison

Semaglutide. Tirzepatide. Retatrutide. These three compounds represent the evolution of incretin-based weight management research — from single-pathway to triple-pathway agonism. If you’re researching GLP-1 peptides and trying to understand the differences, this is the only comparison you need.

This guide breaks down the mechanism of action, clinical trial data, side effect profiles, receptor targets, and practical research considerations for each compound — side by side, backed by published data.

The 30-Second Version: What Makes Each Compound Different

• Semaglutide (Ozempic/Wegovy) — Targets GLP-1 only. The gold standard that proved single-agonist weight management works. ~15% mean weight loss in pivotal trials.
• Tirzepatide (Mounjaro/Zepbound) — Targets GLP-1 + GIP. Proved that dual agonism outperforms single agonism. ~22.5% mean weight loss.
• Retatrutide (Reta GLP-3R) — Targets GLP-1 + GIP + Glucagon. The only triple agonist in late-stage development. ~24.2% mean weight loss — and it increases energy expenditure, not just reduces appetite.

Each step forward adds a receptor target, and each addition has produced measurably better clinical results. The pattern is clear — but the details matter for research design.

Complete Comparison Table

Property	Semaglutide	Tirzepatide	Retatrutide
Brand names	Ozempic, Wegovy, Rybelsus	Mounjaro, Zepbound	Not yet approved
Developer	Novo Nordisk	Eli Lilly	Eli Lilly
Classification	Single agonist	Dual agonist (twincretin)	Triple agonist
Receptor targets	GLP-1	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Peptide size	31 amino acids	39 amino acids	39 amino acids
Max weight loss (trials)	~15% (STEP trials)	~22.5% (SURMOUNT-1)	~24.2% (Phase 2)
Appetite suppression	Strong (GLP-1)	Very strong (GLP-1 + GIP synergy)	Very strong (3-pathway)
Energy expenditure	Minimal increase	Modest increase	Significant increase (glucagon)
Liver fat reduction	Moderate	Significant (MASH data)	Most significant (Phase 2 NAFLD)
FDA status	Approved (obesity + T2D)	Approved (obesity + T2D)	Phase 3 trials
Dosing frequency	Weekly (injectable) or daily (oral)	Weekly	Weekly
Oral formulation	Yes (Rybelsus)	In development	No
Primary side effects	Nausea, vomiting, diarrhea	Nausea, diarrhea, decreased appetite	Nausea, diarrhea, vomiting

Mechanism Comparison: Why More Receptors Means Better Results

Semaglutide: The GLP-1 Foundation

Semaglutide works exclusively through GLP-1 receptor agonism. It was a breakthrough because it demonstrated for the first time that a single-molecule pharmaceutical intervention could produce clinically meaningful weight loss (>10%) in a large percentage of subjects. The mechanism is primarily appetite-centric: GLP-1 receptor activation in the hypothalamus reduces hunger, while activation in the gut slows gastric emptying.

The limitation of single-agonist GLP-1 therapy is that it works almost entirely on the “energy in” side of the equation. It reduces how much you eat, but doesn’t significantly change how much energy you burn.

Tirzepatide: Adding GIP to the Equation

Tirzepatide was the first “twincretin” — a single molecule that activates both GLP-1 and GIP receptors. The SURMOUNT-1 trial proved the hypothesis that dual agonism produces superior results, with mean weight loss of 22.5% at the highest dose compared to semaglutide’s ~15%.

GIP receptor activation adds several effects beyond what GLP-1 alone provides: enhanced insulin secretion, improved lipid metabolism, and emerging evidence for direct effects on adipose tissue. The combination creates a synergistic effect where the total impact exceeds what you’d predict from simply adding GLP-1 and GIP effects together.

Prax Peptides offers tirzepatide as Tirz GLP-2 12mg for researchers studying dual-agonist mechanisms.

Retatrutide: The Triple Agonist Advantage

Retatrutide adds glucagon receptor activation on top of the GLP-1 + GIP dual agonism that tirzepatide already uses. This third pathway is the game-changer for one critical reason: it increases energy expenditure.

While GLP-1 and GIP primarily reduce energy intake (appetite suppression), glucagon receptor activation increases energy output through hepatic fat oxidation (burning liver fat), increased thermogenesis, and mobilization of stored triglycerides. For the first time, a single compound addresses both sides of the energy balance equation — reducing intake AND increasing expenditure — which explains the 24.2% mean weight reduction in the Phase 2 trial.

This glucagon component also makes retatrutide particularly promising for NAFLD/NASH research, where liver fat reduction is the primary outcome of interest.

Clinical Trial Results: Head-to-Head Data

Semaglutide — STEP Trial Program

The STEP (Semaglutide Treatment Effect in People with Obesity) trials established the clinical evidence base for GLP-1 weight management:

• STEP 1: 2.4mg semaglutide weekly produced 14.9% mean weight loss vs 2.4% placebo at 68 weeks
• STEP 2 (T2D patients): 9.6% mean weight loss
• 86.4% of participants achieved ≥5% weight loss
• 69.1% achieved ≥10% weight loss

The STEP program cemented semaglutide as a legitimate weight management tool and sparked the entire GLP-1 agonist research revolution.

Tirzepatide — SURMOUNT Trial Program

SURMOUNT proved that dual agonism outperforms single agonism:

• SURMOUNT-1: 15mg tirzepatide weekly produced 22.5% mean weight loss vs 2.4% placebo at 72 weeks
• 96% of participants achieved ≥5% weight loss
• 63% achieved ≥20% weight loss
• Superior to semaglutide in the SURMOUNT-5 head-to-head trial

Retatrutide — Phase 2 Results

Though still in earlier clinical development, retatrutide’s Phase 2 results exceeded both predecessors:

• Phase 2: 12mg retatrutide weekly produced 24.2% mean weight loss at 48 weeks
• 100% of participants in the 12mg group achieved ≥5% weight loss
• 83% achieved ≥15% weight loss
• 63% achieved ≥20% weight loss

Important caveat: Retatrutide’s data comes from a Phase 2 trial (smaller participant count, shorter duration). Phase 3 results will provide the definitive comparison. However, the magnitude of improvement — 24.2% at just 48 weeks vs tirzepatide’s 22.5% at 72 weeks — is striking and suggests the triple-agonist approach provides meaningful additional benefit.

Side Effect Comparison

All three compounds share a common GI side effect profile because they all activate GLP-1 receptors. However, there are nuances:

Side Effect	Semaglutide	Tirzepatide	Retatrutide
Nausea	44%	24-31%	Dose-dependent, comparable to GLP-1
Diarrhea	30%	18-23%	Reported, typically mild
Vomiting	24%	9-13%	Most common during dose escalation
Constipation	24%	11-17%	Reported
Heart rate increase	Modest	Modest	Small increase in some dose groups
Dose escalation used	Yes	Yes	Yes (critical for tolerability)

All three compounds use dose-escalation protocols to manage GI side effects. The key takeaway is that side effect profiles are broadly similar — the differentiation between these compounds is primarily in efficacy, not tolerability.

Which Compound for Which Research Question?

The choice between semaglutide, tirzepatide, and retatrutide for research depends entirely on what you’re studying:

Choose Semaglutide Research When:

• Studying pure GLP-1 receptor effects without confounding pathways
• You need the most extensive published literature base for comparison
• Investigating oral vs injectable GLP-1 delivery (semaglutide has both)
• Budget constraints — semaglutide is the most widely available GLP-1 compound

Choose Tirzepatide (Tirz GLP-2) Research When:

• Studying GLP-1/GIP synergy and dual-agonist mechanisms
• Investigating insulin sensitivity improvements beyond what GLP-1 alone provides
• Lipid metabolism research where GIP’s role is the variable of interest
• Comparing dual vs single agonism with matched GLP-1 components

Choose Retatrutide (Reta GLP-3R) Research When:

• Studying the metabolic effects of glucagon receptor co-activation
• Energy expenditure research — retatrutide is the only compound that significantly increases metabolic rate
• NAFLD/NASH and hepatic fat metabolism research (glucagon’s liver effects)
• Maximum-efficacy weight management protocols
• Triple vs dual agonist comparative studies

The Future: Beyond Triple Agonism

The progression from semaglutide (single) to tirzepatide (dual) to retatrutide (triple) raises an obvious question: what comes next? Researchers are already investigating quadruple and quintuple agonists that add receptors like amylin and potentially GLP-2 to the mix. For a deep dive into what’s on the horizon, see our article on the quintuple agonist and next-generation weight loss research.

Other Prax Peptides products for metabolic research include MOTS-C (mitochondrial-derived peptide), SLU-PP-332 (exercise mimetic), Tesofensine (triple reuptake inhibitor), and Tesamorelin (GHRH analog).

Shop GLP-1 Research Peptides

Frequently Asked Questions

Which is stronger — retatrutide, tirzepatide, or semaglutide?

Based on published clinical trial data, retatrutide has produced the highest mean weight reduction (24.2% at 48 weeks), followed by tirzepatide (22.5% at 72 weeks), then semaglutide (15% at 68 weeks). However, “stronger” depends on the specific outcome measure — for pure appetite suppression, the differences may be smaller than for overall weight loss.

Why does adding more receptors produce better results?

Each additional receptor pathway addresses a different aspect of metabolic regulation. GLP-1 reduces appetite. GIP enhances insulin sensitivity and lipid metabolism. Glucagon increases energy expenditure and burns liver fat. By targeting all three simultaneously, retatrutide affects both energy intake and energy output — the full energy balance equation.

Will retatrutide replace semaglutide and tirzepatide?

Not necessarily. Even if retatrutide achieves FDA approval, each compound has research value. Semaglutide provides the cleanest model for studying isolated GLP-1 effects. Tirzepatide is essential for understanding GLP-1/GIP synergy. Retatrutide’s value is specifically in protocols where triple agonism is the mechanism under investigation.

Can these compounds be combined in research?

Published clinical data exists only for each compound as monotherapy. Combination protocols between GLP-1 agonists are not established in the literature and would need to be designed with appropriate oversight and safety considerations.

Where can I find dosage calculations for these peptides?

Use the Prax Peptides reconstitution calculator — it works for any peptide. Enter the vial size, desired solvent volume, and target dose, and it calculates the exact syringe volume. For detailed retatrutide-specific protocols, see our complete retatrutide research guide.

Disclaimer: All compounds discussed are sold for research purposes only. This content is for educational and informational purposes and does not constitute medical advice. These products are not approved by the FDA for human use. Consult applicable regulations in your jurisdiction before purchasing research peptides.